✉news HealthMedicine first seen 10 h ago, last 23 min ago, peak #27
Obesity expert calls for an end to compounded weight-loss drugs
Original: I’m an obesity expert and can’t wait for the compounding craze to stop
An obesity medicine specialist writing in Fortune argues the booming practice of compounding copycat versions of popular weight-loss drugs like Ozempic and Wegovy should end. The expert warns compounded semaglutide lacks the oversight and quality control of approved medications, raising safety concerns for patients using cheaper alternatives amid ongoing shortages of the brand-name injections.
Why now: GLP-1 drug shortages and the rise of cheaper compounded alternatives have made their safety a hot topic in obesity medicine.
FortuneOzempicWegovysemaglutideNovo Nordisk
Rank over time, top of the chart is #1. 7 snapshots from 10 h ago to 23 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/866291